newsportalnew

Exciting announcement: Zenith Drugs IPO has been launching soon

Zenith Drugs IPO

Exciting announcement! The renowned NSE SME Exchange will host the IPO debut of Jenith Drugs Limited,(Zenith Drugs IPO) according to the company’s announcement.

This IPO has a massive issue size of INR 40.68 crores, and you know what? All of the shares are new! The period for submitting an IPO application is February 19–22, 2024. The offer price for an IPO application ranges from INR 75 to INR 79 per share, with a lot size of 1600 shares. Each share has a face value of INR 10. As an alternative, you can review the multiples proposal document.

Keep checking this page for the most recent information on Jenith Drugs’ IPO, including the company’s overview, financials, live subscription status, allocation data, GMP, and more. Take advantage of this chance without fail!”

About Zenith Drugs

Jenith Drugs Limited is a pharmaceutical manufacturing and trading company based in Indore, established in 2000. They have a manufacturing facility ensuring the highest quality standards in pharmaceutical production.

Jenith Drugs excels in producing high-quality and affordable medicines for needy patients, including cost-effective generic drugs  the company has been dedicated to building the structure and laying the groundwork required for its future growth and success, with a focus on providing low-income patients with access to high-quality, reasonably priced drugs. medications.

– Goal: Provide superior medical services and become a top premium pharmaceutical company in India and globally, focusing on affordable healthcare.

– Approach: Emphasize core competencies and technology-driven strategies for excellence.

– Commitment: Maintain high service standards and continuously expand to meet customer needs.

– Vision: Ensure accessibility and quality in healthcare for all.

Details of Zenith Drugs IPO

SME IPO Issue Opening Date:19th Feb 2024
SME IPO Issue Closing Date:22nd Feb 2024
SME IPO Issue Price:₹75.00-79.00 Per Share
IPO Listing At:NSE SME
Retail Quota:Not less than 35% of the Net Issue
SME IPO Issue Type:Book Build Issue
SME IPO Issue Size:₹40.68 Cr
Fresh Issue:₹40.68 Cr
Face Value:₹10 Per Equity Share

Important Dates of Zenith Drugs IPO

Get important updates regarding Zenith Drugs IPO. Opening, closing, allotment, and listing dates. Dates are updated as they are announced.

Zenith Drugs IPO dates
SME IPO ActivityDate
Basis of Allotment Date*23rd Feb 2024
SME IPO Listing Date*27th Feb 2024

GMP Of Zenith Drugs IPO

last GMP is ₹18,of Zenith Drugs IPO till Feb 21st 2024 1:28 PM. estimated listing price is ₹91 With the price band of 79.00, of Zenith Drugs  IPO 

Zenith Drugs IPO Strengths

– Strong sales, marketing, and distribution capabilities

– Experienced promoters and management team

– Cost efficiency

– Formulation & development

– Regulatory compliance

– Global reach

– Product portfolio

– Supply chain efficiency

– Scalable business model

Zenith Drugs IPO Objective

Updated information/data has been leaked on the websites of National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) and changes are reported in real time. Please visit the respective websites for latest information/data. The information/data provided here is for Buddhists only and is provided by Chittorgarh.com on “as is” and “as available” basis and without any disposition, purpose or implication

Chittorgarh.com does not guarantee the accuracy, adequacy or completeness of the information obtained by you through the above websites. Chittorgarh.com will not be liable in any way for any discrepancy, error, omission, loss or damage.Chittorgarh.com, its affiliates and including its directors, employees and employees, will not be liable for any loss, damages of any kind, including direct, indirect, punitive, exemplary, consequential damages and lost profits arising in any way Not limited to profits.

, Excluding the use of information/data obtained through the said websites. The recipient alone is solely responsible/liable for any decisions taken based on this information/data. All recipients should conduct their own research and seek appropriate professional advice before relying on the said information.

Exit mobile version